Skip to content
Medical Health Aged Care

Meet Charlie, Westmead Private Hospital’s newest team member

Ramsay Health Care 2 mins read
Key Facts:
  • 10-year-old golden retriever Charlie joins Westmead Private Hospital as a therapy dog, accompanied by owner Julie Quinn
  • The therapy dog program aims to support patient wellbeing and is part of the hospital's holistic approach to health care
  • Charlie's gentle nature and love of people makes her particularly well-suited for the therapy dog role

Patients and visitors at Westmead Private Hospital are being greeted by a very special new team member: Charlie, a 10-year-old golden retriever with a talent for lifting spirits.

Charlie has officially started her new “role” as a therapy dog at the hospital, visiting wards and common areas alongside her owner, Julie Quinn.

Together, they are helping create small but meaningful moments of connection for people who may be feeling anxious, unwell or far from home.

Julie from Paws Pet Therapy said Charlie was made for the job.

“Charlie absolutely loves people. She lights up when someone stops to pat her. She has such a gentle nature and seems to know when someone needs a little extra comfort,” Julie said.

While new to Westmead Private Hospital, Charlie is no stranger to hospital corridors. She has previously visited other sites including rehabilitation and children’s hospitals and an aged care facility.

Therapy dog visits are designed to complement clinical care by supporting patient wellbeing. A friendly visit from Charlie can offer a welcome distraction before a procedure, encourage conversation, or simply bring a smile during a challenging time.

Andrew Spillane, CEO of Westmead Private Hospital which is part of Ramsay Health Care, said Charlie’s visits reflect the hospital’s commitment to caring for the whole person.

“Health care is about more than medical treatment. It’s about compassion, connection and creating an environment where people feel supported,” Mr Spillane said.

“Charlie and Julie bring warmth and joy to our hospital community, and we’re delighted to welcome them as regular visitors.”


Contact details:

Media enquiries: [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 04/03/2026
  • 10:56
Roots

Roots Corporation Announces Strategic Review

TORONTO–BUSINESS WIRE– Roots Corporation (“Roots,” or the “Company”) (TSX: ROOT) announced that its Board of Directors (the “Board”) has initiated a review of strategic…

  • Contains:
  • Medical Health Aged Care
  • 04/03/2026
  • 08:56
Monash University

Monash University and Seaport Therapeutics Awarded up to $21 Million AUD from ARPA-H to Advance GlyphCeleTM, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function

ARPA-H award supports the development of an oral prodrug, based on the Glyph™ platform initially developed at the Monash Institute of Pharmaceutical Sciences (MIPS), to address dysfunctional gut lymphatics linked to metabolic disease and pancreatic cancer. Monash University has announced the award of support from the Advanced Research Projects Agency for Health (ARPA-H) to advance an oral prodrug of celecoxib – using the GlyphTM platform and designed to deliver therapy directly to the gut lymphatics – aiming to improve lymphatic function and advance the treatment of metabolic disease and pancreatic cancer by directly addressing local inflammation and lymphatic dysfunction. The…

  • Medical Health Aged Care, Women
  • 04/03/2026
  • 06:00
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

STRIVE clinical trial now available in Aotearoa New Zealand to improve outcomes in vulvar cancer

MEDIA RELEASE: Wednesday,4March2025 The Australian New Zealand Gynaecological Oncology Group (ANZGOG) in partnership with the Canadian Cancer Trials Group (CCTG) announces the local opening of theSTRIVEclinical trial– Stratification of Vulvar Squamous Cell Carcinoma by HPV and p53 status to Guide Excisionclinical trial (CCTG Protocol VU.2; ANZGOG Protocol ANZGOG2109/2021). STRIVErepresentsan important stepforward in advancing evidence-based surgical management for women diagnosed with vulvar squamous cell carcinoma (VSCC). About the STRIVE Trial STRIVE is an international, prospective, stratification study designed to refine surgical decision-making for patients withprimary vulvar squamous cell carcinoma(VSCC) based ontumourbiology. The study is led globally by the CCTG and led…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.